I'll let Dr. Yarrow speak to the low-level presence issue. He knows it far better than I.
It was interesting. I was just speaking right before the meeting, in fact, with your colleague Mr. Allen. Nowhere are we trying to change European attitudes on biotech or trying to sell them, if you will, on a particular vision. This is about facilitating trade. What had happened previously—Stephen can expand better on the details than I can—is that trade was being held up due to issues of low-level presence. In no way are we trying to prejudge the attitudes of EU member nations on those products; we simply want to facilitate trade of products they want—